Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has completed its acquisition of New Zealand-based Volpara Health Technologies. The acquisition, completed over an eight-month period, represents a significant step in Lunit’s mission to advance AI-driven cancer care. Lunit, headquartered in Seoul with offices in the US, Europe, and Asia, plans to integrate Volpara’s advanced breast health platform into its own AI solutions, creating a comprehensive suite for cancer detection. This merger is expected to enhance Lunit’s technological capability, market presence, and drive forward advancements in global healthcare. Lunit’s CEO, Brandon Suh, emphasized the strategic importance of Volpara’s established US presence, which comprises over 2,000 medical sites. Volpara’s CEO, Teri Thomas, also highlighted the potential for improved early cancer detection and patient outcomes. Lunit’s recent publication milestone, with over 100 peer-reviewed papers, further underscores its commitment to medical AI research.

Healthcare Technology, Artificial Intelligence, Medical Devices & Diagnostics,South Korea, New Zealand, United States, Global